Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
RESEARCH TOOLSreports
Holding NAMS?
Track your performance easily
NAMS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.90 - $26.35
Previous Close$20.01
Volume1.18M
Average Volume (3M)426.93K
Market Cap
$2.19B
Enterprise Value$1.77B
Total Cash (Recent Filing)$422.73M
Total Debt (Recent Filing)$506.00K
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Mar 28, 2025EPS Estimate
-$0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding92,385,872
10 Day Avg. Volume899,272
30 Day Avg. Volume426,931
Standard Deviation0.21
R-Squared0.00074
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)4.88
Price to Sales (P/S)66.72
Price to Cash Flow (P/CF)-43.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue56.24
Enterprise Value/Gross Profit125.30
Enterprise Value/Ebitda-32.19
Forecast
1Y Price Target
$37.67Price Target Upside87.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
NewAmsterdam Pharma Company News
PremiumCompany Announcements
NewAmsterdam Pharma Reports Promising Phase 3 Trial Results
PremiumCompany Announcements
NewAmsterdam Pharma’s Promising Phase 3 Trial Results
PremiumCompany Announcements
NewAmsterdam Pharma Reports Strong Q3 and Trial Progress
Bulls Say, Bears Say
Bulls Say
Clinical TrialsTwo upcoming phase 3 trial readouts can confirm obi's impressive LDL-C lowering and attractive safety/tolerability profile.
Market PotentialIf successful, obi is expected to generate blockbuster sales by addressing unmet needs in the ~30MM patients unable to meet LDL-C targets with current therapies.
Regulatory And PatentRecently issued composition of matter patent for obi extends IP protection in the US into 2043, providing a longer runway for obi sales to ramp if approved.
Bears Say
Clinical Trial RisksIf obicetrapib shows much lower efficacy in both Ph.3 trials and severe unexpected safety signals emerge, this could yield 60-80% downside in the stock.
Efficacy ConcernsLDL improvement may be slightly below investor expectations.
Stock VolatilityIntraday volatility in NAMS stock seems to track with the fact that obi’s ~36% mean LDL-C reduction could be slightly below some investors’ expectations.
---
Ownership Overview
8.28% Insiders
1.10% Mutual Funds
77.00% Other Institutional Investors
13.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NAMS FAQ
What was NewAmsterdam Pharma Company’s price range in the past 12 months?
NewAmsterdam Pharma Company lowest stock price was $8.90 and its highest was $26.35 in the past 12 months.
What is NewAmsterdam Pharma Company’s market cap?
Currently, no data Available
When is NewAmsterdam Pharma Company’s upcoming earnings report date?
NewAmsterdam Pharma Company’s upcoming earnings report date is Mar 28, 2025 which is in 126 days.
How were NewAmsterdam Pharma Company’s earnings last quarter?
NewAmsterdam Pharma Company released its earnings results on Nov 06, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.499 by $0.319.
Is NewAmsterdam Pharma Company overvalued?
According to Wall Street analysts NewAmsterdam Pharma Company’s price is currently Undervalued.
Does NewAmsterdam Pharma Company pay dividends?
NewAmsterdam Pharma Company does not currently pay dividends.
What is NewAmsterdam Pharma Company’s EPS estimate?
NewAmsterdam Pharma Company’s EPS estimate is -$0.52.
How many shares outstanding does NewAmsterdam Pharma Company have?
NewAmsterdam Pharma Company has 92,385,870 shares outstanding.
What happened to NewAmsterdam Pharma Company’s price movement after its last earnings report?
NewAmsterdam Pharma Company reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.499. Following the earnings report the stock price went up 13.734%.
Which hedge fund is a major shareholder of NewAmsterdam Pharma Company?
Among the largest hedge funds holding NewAmsterdam Pharma Company’s share is RA Capital Management. It holds NewAmsterdam Pharma Company’s shares valued at 134M.
---
NewAmsterdam Pharma Company Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.67 (87.23% Upside)
$37.67 (87.23% Upside)
Blogger Sentiment
Bullish
NAMS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 937.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $608.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 30.7%
Last 30 Days ▲ 30.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Company Description
NewAmsterdam Pharma Company
Frazier Lifesciences Acquisition Corp is a blank check company.
---
NAMS Stock 12 Month Forecast
Average Price Target
$37.67
▲(87.23% Upside)
Technical Analysis
Best Analysts Covering NAMS
1 Year
1 Year Success Rate
10/14 ratings generated profit
1 Year Average Return
+35.96%
reiterated a buy rating 16 days ago
Copying Roanna Ruiz's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +35.96% per trade.
---